GlassScriptPhysician profile
Alan D Deutsch
NPI 1528040011
$16,796.56
in general payments reported to CMS, 2019-2025
73 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,336 · 2020: $2,028 · 2021: $2,874 · 2022: $2,369 · 2023: $2,611 · 2024: $2,459 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,189.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,215.64 | 2019-2025 | |
| Abbvie INC. | $1,670.78 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $1,044.01 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ucb, INC. | $990.24 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Pfizer INC. | $858.42 | 2019-2025 | |
| Biogen, INC. | $740.19 | 2019-2024 | Vumerity, Tysabri, Spinraza |
| Celgene Corporation | $734.53 | 2021-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $700.18 | 2019-2025 | Ultomiris, Soliris |
| Emd Serono, INC. | $661.31 | 2019-2025 | Mavenclad |
| Lilly USA, LLC | $640.00 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Genzyme Corporation | $498.98 | 2019-2025 | |
| Eisai INC. | $347.98 | 2019-2025 | |
| Grifols USA, LLC | $341.35 | 2019-2025 | Gamunex-C |
| Lundbeck LLC | $327.27 | 2019-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $296.71 | 2022 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Deutsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.